EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Liraglutide for Children 6 to

Claudia K Fox iD, Margarita Barrientos-Pérez, Eric M Bomberg, John Dcruz, Inge Gies, Nina M Harder-Lauridsen, Muhammad Yazid Jalaludin, Kushal Sahu, Petra Weimers, Thomas Zueger, Silva Arslanian iD, SCALE Kids Trial Group

New England Journal of Medicine · 06.02.2025 · 392 (6) · 555-565

DOI: 10.1056/nejmoa2407379 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 06.02.2025. Verfasst von Claudia K Fox und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Pediatric Obesity Medicine, Department of Pediatrics, University of Minnesota Medical School, Minneapolis. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Liraglutide, Pediatric Obesity, Weight Loss. Die Arbeit wurde bisher 143-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: NIDDK NIH HHS, Novo Nordisk A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: No medications are currently approved for the treatment of nonmonogenic, nonsyndromic obesity in children younger than 12 years of age. Although the use of liraglutide has been shown to induce weight loss in adults and adolescents with obesity, its safety and efficacy have not been established in children. METHODS: In this phase 3a trial, which consisted of a 56-week treatment period and a 26-week follow-up period, we randomly assigned children (6 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Obesity AgentsLiraglutidePediatric ObesityWeight LossGlucagon-Like Peptide-1 Receptor AgonistsChildFemaleHumansMaleBody Mass IndexDouble-Blind MethodInjections, SubcutaneousLife StyleGastrointestinal DiseasesTreatment OutcomeFollow-Up Studies

Substanzen

Anti-Obesity AgentsLiraglutideGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Center for Pediatric Obesity Medicine, Department of Pediatrics, University of Minnesota Medical School, Minneapolis.
  • Pediatric Endocrinology, Hospital Ángeles Puebla, Puebla City, Mexico.
  • Division of Endocrinology, Department of Pediatrics, University of Minnesota Medical School, Minneapolis.
  • Novo Nordisk Global Business Services, Bangalore, India.
  • Division of Pediatric Endocrinology, Department of Pediatrics, Universitair Ziekenhuis Brussel, Brussels.
  • Novo Nordisk, Søborg, Denmark.

ORCID-Profile: Claudia K Fox, Silva Arslanian

Förderung

  • NIDDK NIH HHS
  • Novo Nordisk A/S

Zitieren

APA

Fox, C. K., Barrientos-Pérez, M., Bomberg, E. M., Dcruz, J., Gies, I., Harder-Lauridsen, N. M., Jalaludin, M. Y., Sahu, K., Weimers, P., Zueger, T., Arslanian, S., & SCALE Kids Trial Group (2025). Liraglutide for Children 6 to. New England Journal of Medicine, 392(6), 555-565. https://doi.org/10.1056/nejmoa2407379

Vancouver

Fox CK, Barrientos-Pérez M, Bomberg EM, Dcruz J, Gies I, Harder-Lauridsen NM, et al. Liraglutide for Children 6 to. New England Journal of Medicine. 2025;392(6):555-565. doi:10.1056/nejmoa2407379

BibTeX
@article{Fox2025,
  author = {Fox, Claudia K and Barrientos-Pérez, Margarita and Bomberg, Eric M and Dcruz, John and Gies, Inge and Harder-Lauridsen, Nina M and Jalaludin, Muhammad Yazid and Sahu, Kushal and Weimers, Petra and Zueger, Thomas and Arslanian, Silva and SCALE Kids Trial Group, SCALE Kids Trial Group},
  title = {Liraglutide for Children 6 to},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {6},
  pages = {555--565},
  doi = {10.1056/nejmoa2407379}
}
Kostenlos starten →